15 results about "Cellular synthesis" patented technology

The invention provides a 19F streptococcus pneumoniae invasiveness risk prediction method, and relates to the technical field of molecular biology. Wherein the evaluation marker combination comprises a translation genome, a cell synthesis genome and a ligand transport metabolism genome; the translation genome comprises rluB and rsmE; the cell synthetic genome comprises mscL and murI; and the ligand transport metabolism genome comprises czcD, site B, mtsC and pstS. The evaluation marker combination can accurately evaluate the invasive risk of serotype 19F streptococcus pneumoniae, and realizes molecular typing and risk prediction. The kit has high sensitivity and specificity, is suitable for high-throughput detection, and is helpful for clinical diagnosis and pathogenic mechanism research.

The invention discloses a methyltransferase mutant as well as a coding gene, a vector, recombinant bacteria and application thereof, and belongs to the technical field of enzyme engineering. According to the invention, variants EgtDT163G, M252V and E282A of methyltransferase EgtD from M. smegmais ATCC700084 are mutated, Pro at the 35 site is mutated into Cys, Lys at the 36 site is mutated into Arg, Phe at the 38 site is mutated into Leu, Thr at the 168 site is mutated into Phe, the methylation catalytic efficiency with L-tryptophan as a substrate is obviously improved, and the L-erythrinine is efficiently synthesized. On the basis that the L-erythrinine is synthesized by using E. coli whole cells, a further theoretical and technical basis is provided for establishing an industrial production process of the L-erythrinine, which is low in production cost, high in production intensity and small in environmental pollution.

A prenyltransferase capable of producing bakuchiol or its analogues from geranyl pyrophosphate (GPP) and cinnamic acid, coumaric acid, caffeic acid and / or ferulic acid is disclosed herein. Manipulated cells expressing a prenyltransferase capable of producing bakuchiol or its analogues, as well as methods of using the prenyltransferase and cells to produce bakuchiol or its analogues, are also disclosed herein.

The invention relates to a modified strain and application thereof in PDRN production, and belongs to the technical field of microorganisms. The technical problems that in the prior art, extraction of PDRN is limited by raw materials (fish testis), the price is high and scarce, and the effects of enhancing cell viability and promoting cell collagen synthesis are poor are solved. The invention provides a strain of Escherichia coli 4-16, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on October 14, 2025, and the preservation number is CGMCC No.36169; the recombinant PDRN prepared from the Escherichia coli has remarkable effects in promoting cell migration, improving cell activity and promoting cell synthesis of collagen, and has huge application potential in the fields of medicine, medical beauty and the like.

The invention provides a cell-free toxin synthesis system and method. The system at least comprises: (1) a cell-free system; (2) an amplification system containing amplified plasmids of the cell-free system is added, the plasmids are plasmids containing coding toxin protein, the amplification system containing the amplified plasmids is obtained after the plasmids are added into the amplification system according to the preset concentration to be amplified, the preset concentration is 2-10 ng / mu L, and the preset concentration is not 2 ng / mu L. According to the method, plasmids with a certain concentration are added into a cell-free reaction system, so that the in-vitro expression efficiency of toxins is effectively improved, and particularly, the purification efficiency is more obviously improved.

The application provides a reaction system and method for synthesizing a cell-free sweet protein, characterized by comprising: 1) a cell-free reaction system; and 2) a nucleic acid encoding the sweet protein. The system and method can be used to synthesize various sweet proteins, which indicates that the system and method disclosed by the application are universal for the synthesis of sweet proteins, and the sweet proteins purified by the system and method have a high concentration. In addition, the method is simple and the reaction conditions are mild, and is particularly suitable for industrial production.

The application provides an application of dodartin A1 in activating NK cells. Through in-vitro experiments, it is proved that dodartin A1 can significantly promote the synthesis and release of IFN-gamma and cytotoxic substances (such as granzyme B and perforin) of NK92 cells, and increase the expression of the surface agonistic receptors NKp46 and NKG2D of the NK92 cells; through in-vivo experiments, it is proved that dodartin A1 can promote the expression of the NK cell activation related substances CD107a and NKp46 to play an anti-hepatoma effect; in conclusion, dodartin A1 has the effect of activating NK cells.

The invention provides a composite additive and application thereof in mammalian cell culture, and relates to the technical field of cell culture, the composite additive comprises a pyrimidine nucleoside precursor, vitamin, amino acid, a TCA circulation intermediate product and metal ions; wherein the deoxyuridine is used as a pyrimidine nucleoside precursor and can promote cell DNA synthesis so as to improve the peak living cell density; pyridoxine hydrochloride and choline chloride synergistically regulate amino acid metabolism and enhance the antibody synthesis efficiency; magnesium is an activating agent of mitochondrial key enzymes such as pyruvate dehydrogenase and citrate synthase and can improve the ATP generation efficiency and provide more energy for antibody synthesis, alpha-ketoglutaric acid optimizes tricarboxylic acid circulation to supply energy, the cell activity in a low-iron environment is guaranteed, finally, multi-channel synergistic interaction is achieved, the cell density and the antibody yield are improved, and the product quality is improved. And the key quality attribute of the antibody is not changed. The technical problem that a culture medium in the prior art cannot coordinate the balance of cell density, antibody yield and charge heterogeneity in a low-iron environment is solved.

The application belongs to the technical field of mass spectrometry, and particularly relates to a mass spectrometry detection method and application of intracellular blood coagulation factor X, which comprises the following steps: specifically enriching ectopic synthesis of blood coagulation factor X in tumor cells to obtain a protein sample; performing protein sample fixation and treatment on the protein sample by using SDS-PAGE gel electrophoresis, placing the gel in an ice box after scanning the gel by using a gel imaging system, and storing the gel; performing in-gel enzymatic digestion on the blood coagulation factor X in the gel to obtain a peptide segment solution; detecting the endogenous synthesis of blood coagulation factor X in tumor cells by using mass spectrometry technology, and obtaining mass spectrometry data. The application firstly adopts the mass spectrometry technology to detect the blood coagulation factor X synthesized by tumor cells outside normal liver cells, specifically enriches the ectopic synthesis of blood coagulation factor X in glioma cells by using the protein immunoprecipitation technology, performs SDS-PAGE gel electrophoresis, performs in-gel enzymatic digestion, and detects the endogenous synthesis of blood coagulation factor X in tumor cells by using the mass spectrometry technology.

The present application relates to a modified strain and its application in PDRN production, belonging to the field of microbial technology. The technical problem to be solved is that the extraction of PDRN in the prior art is limited by raw materials (fish testes), is high in price, is scarce, and has poor effect in enhancing cell activity and promoting cell synthesis of collagen. The present application provides an Escherichia coli 4-16, which has been preserved in the China General Microbiological Culture Collection Center on October 14, 2025, with a preservation number of CGMCC No. 36169. The recombinant PDRN prepared from the E. coli has a significant effect in promoting cell migration, enhancing cell activity, and promoting cell synthesis of collagen, and has great application potential in the fields of medicine, medical beauty, etc.

The application belongs to the technical field of bioactive peptides and polypeptide engineering, and specifically discloses a novel sleep-regulating nonapeptide isolated from Symplectoteuthis oualaniensis and a targeted enzymatic preparation method thereof, and the primary structure sequence of the nonapeptide is Trp-Ala-Gly-Gly-Asn-Ala-Ser-Gly-Lys (WAGGNASGK). The application uses the protein isolated from the body wall of Symplectoteuthis oualaniensis as raw material, and sequentially adopts protease from thermophilic bacteria and trypsin for directional double-enzyme hydrolysis, and the target nonapeptide is efficiently obtained through membrane filtration and chromatography purification. The target nonapeptide has the effects of promoting the production of gamma-aminobutyric acid by astrocytes and promoting the synthesis of 5-hydroxytryptamine by human neuroblasts, and has application value in regulating sleep and improving sleep disorders.

The invention discloses a ormosine methyltransferase mutant as well as a coding gene, a vector, recombinant bacteria and application thereof, and belongs to the technical field of enzyme engineering. According to the invention, mutagenesis is carried out on variants EgtDM252V and E282A of methyltransferase EgtD from M. smegmais ATCC700084, Pro at the 34 site is mutated into Lys, Thr at the 213 site is mutated into Ser, Ser at the 284 site is mutated into Ala, the methylation catalytic efficiency with L-ormosin as a substrate is obviously improved, and the L-erythrinine is efficiently synthesized. On the basis that the L-erythrinine is synthesized by using E. coli whole cells, a further theoretical and technical basis is provided for establishing an industrial production process of the L-erythrinine, which is low in production cost, high in production intensity and small in environmental pollution.

The invention belongs to the field of bioactive peptide technology and polypeptide engineering, and particularly discloses a novel sleep regulation nonapeptide separated from Sthenoteuthoualensis and a targeted enzymolysis preparation method of the novel sleep regulation nonapeptide, and the primary structure sequence of the nonapeptide is Trp-Ala-Gly-Gly-Asn-Ala-Ser-Gly-Lys (WAGGNASGK). The invention further discloses a preparation method of the novel sleep regulation nonapeptide. The method comprises the following steps: by taking isolated protein from the body wall of the plinoteuthis teualthensis as a raw material, sequentially carrying out directional double-enzyme enzymolysis by adopting thermolysin and trypsin, and carrying out membrane filtration and chromatographic purification, so as to efficiently obtain the target nonapeptide. The target nonapeptide has the effects of promoting astrocytes to generate gamma-aminobutyric acid and promoting human neuroblasts to synthesize 5-hydroxytryptamine, and has application value in the aspects of regulating sleep, improving sleep disorders and regulating circadian rhythm.

Methods of stimulating production of specialized pro-resolving mediators (SPMs) by mesenchymal stem cells (MSCs) are provided. The methods include contacting MSCs with one or more SPM fatty acid precursors, SPM intermediates, or a combination of two or more thereof. Also provided are compositions including the stimulated MSCs or conditioned media from the stimulated MSCs. Methods of treating or inhibiting inflammation are also provided, including administering to a subject stimulated MSCs or conditioned media from stimulated MSCs.

The invention discloses a method for improving the fermentation yield of human milk oligosaccharides, belongs to the technical field of human milk oligosaccharides, and solves the problems of how to optimize a fermentation process and realize effective synthesis of 2 '-FL by taking glucose and lactose as substrates due to the fact that a microbial whole-cell synthesis method of 2'-FL has the characteristics of mild conditions, low cost and the like and is the most common 2 '-FL synthesis method. Comprising the following steps: S1, transferring activated glycerol tube seeds into a slant culture dish for culture, and then inoculating the seeds into a seed shake flask for culture; s2, inoculating the seeds in the step S1 into a fermentation container for fermentation; s3, fermentation is conducted for 48 h, sucrose laurate is added, and fermentation is continued. In the later period of fermentation, the surfactant is added, so that the permeability of a cell membrane structure is improved, absorption of glucose and lactose and excretion of human milk oligosaccharide are promoted, the fermentation period is prolonged, the fermentation yield is increased, sucrose laurate has low toxicity and biodegradability, and the sucrose laurate has the advantages of being environmentally friendly and free of pollution. The pollution to the environment can be reduced, and the safety of the product can be ensured.